Advertisement

Combined Modality Therapy for Early Stage Operable and Locally Advanced Potentially Resectable Non-Small Cell Lung Carcinoma

  • Joseph I. Clark
  • Kathy S. Albain
Part of the Cancer Treatment and Research book series (CTAR, volume 105)

Abstract

Surgical resection of non-small cell lung carcinoma (NSCLC) remains the primary treatment for early stage disease, that is, stage I and II disease. Yet, the vast majority of patients with lung cancer present with either distant metastatic disease (stage IV) or locally advanced NSCLC (stage IIIA and IIIB). Today, despite modest gains in outcome in patients with early stage disease, using improved surgical techniques, better preoperative risk assessment, and advances in thoracic anesthesia, a significant proportion of these patients will eventually succumb to their disease due to local and/or distant recurrence. For those patients with locally advanced NSCLC, defined either by the presence of mediastinal nodal involvement or a primary tumor that invades key thoracic elements (chest wall, vertebral body, great vessels) surgical resection of this tumor is either difficult (T3) or impossible (T4). Therefore, a combined modality approach to the treatment of most operable or potentially resectable non-small cell lung cancers has been actively pursued by clinical investigators.

Keywords

Induction Therapy Induction Chemotherapy Small Cell Lung Carcinoma Combine Modality Therapy Stage IlIA 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Strauss GM, Langer MP, Elias AD, Skarin AT, Sugarbaker DJ. Multimodality treatment of stage IIIA non-small cell lung carcinoma: A critical review of the literature and strategies for future research. J Clin Oncol 10:829–838, 1992.PubMedGoogle Scholar
  2. 2.
    Rusch VW, Benfield JR. Neoadjuvant therapy for lung cancer: A note of caution. Ann Thor Surg 55:820–821, 1993.CrossRefGoogle Scholar
  3. 3.
    Green M, Bordin O, Choi N et al. Pre-operative and post-operative treatments in stage III NSCLC. Lung Cancer 10(suppl.):S15–S17, 1994.PubMedCrossRefGoogle Scholar
  4. 4.
    Johnson DH, Piantadosi S. Chemotherapy for resectable stage III non-small cell lung cancer — Can that dog hunt? J Natl Cancer Inst 86:650–651, 1994.PubMedCrossRefGoogle Scholar
  5. 5.
    Edelman MJ, Gandara DR, Roach M III, Benfield JR. Multimodality therapy in stage III non-small cell lung cancer. Ann Thorac Surg 61:1564–1572, 1996.PubMedCrossRefGoogle Scholar
  6. 6.
    Albain KS. Induction chemotherapy with or without radiation followed by surgery in stage III non-small lung cancer: Update and perspectives. Oncology 11(suppl. 9):51–57, 1997.Google Scholar
  7. 7.
    Perry MC, Deslauriers J, Albain KS et al. Induction treatment for resectable non-small cell lung cancer: A consensus report. Lung Cancer 17(suppl. 1):15–18, 1997.CrossRefGoogle Scholar
  8. 8.
    Holmes EC, Bleehen NM, Chevalier TL et al. Postoperative adjuvant treatments for non-small lung cancers: A consensus report. Lung Cancer 7:11–13, 1991.CrossRefGoogle Scholar
  9. 9.
    Martini N, Flehinger BJ, Zaman M, Beattie EJ. Results of resection in non-out cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg 198:386–397, 1983.CrossRefGoogle Scholar
  10. 10.
    Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Amer 67:1037–1049, 1987.Google Scholar
  11. 11.
    Vansteenkiste JF, De Leyn PR, Deneffe GJ, Lerut TE, Demedts MG. Clinical prognostic factors in surgically treated stage IIIAN2 non-small cell lung cancer: Analysis of the literature. Lung Cancer 19:3–13, 1998.PubMedCrossRefGoogle Scholar
  12. 12.
    Gordon GS, Vokes EE. Chemoradiation for locally advanced, unresectable NSCLC: New standard of care, emerging strategies. Oncology 13:1075–1088, 1999.PubMedGoogle Scholar
  13. 13.
    Dillman RO, Seagren SL, Propert KJ et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III nonsmall-cell lung cancer. N Engl J Med 323:940–945, 1990.PubMedCrossRefGoogle Scholar
  14. 14.
    Bromley LL, Szur L. Combined radiotherapy and resection for carcinoma of the bronchus: Experience with 66 patients. Lancet 2:937–941, 1955.CrossRefGoogle Scholar
  15. 15.
    Bloedorn RG, Cowley RA, Cuccia CA, Mercado R. Combined therapy with irradiation and surgery in the treatment of bronchogenic carcinoma. Am J Roentgenol 85:875–885, 1961.Google Scholar
  16. 16.
    Shields T, Higgins G, Lawton KR, Heilbrunn A, Khean RJ. Preoperative x-ray therapy as an adjuvant in the treatment of bronchogenic carcinoma. J Thorac Cardiovasc Surg 59:49–61, 1970.PubMedGoogle Scholar
  17. 17.
    Warram J. Preoperative irradiation of cancer of the lung: Final report of a therapeutic trial. A collaborative study. Cancer 36:914–923, 1975.Google Scholar
  18. 18.
    Sherman DM, Neptune WB, Weichselbaum R et al. An aggressive approach to marginally resectable lung cancer. Cancer 41:2040–2045, 1978.PubMedCrossRefGoogle Scholar
  19. 19.
    Payne DG. Pre-operative radiation therapy in non-small cell cancer of the lung. Lung Cancer 7:47–56, 1991.CrossRefGoogle Scholar
  20. 20.
    Lad, T, Wagner H, Piantadosi, S for the Lung Cancer Study Group. Randomized phase II evaluation of pre-operative chemotherapy alone and radiotherapy alone in stage IIIA non-small cell lung cancer. Proc Amer Soc Clin Oncol 10:258, 1991.Google Scholar
  21. 21.
    Skarin A, Jochelson M, Sheldon T et al. Neoadjuvant chemotherapy in marginally resectable stage III MO non-small cell lung cancer: Long-term follow-up in 41 patients. J Surg Oncol 40:266–274, 1989.PubMedCrossRefGoogle Scholar
  22. 22.
    Eagan RT, Ruud C, Lee RE et al for the Lung Cancer Study Group. Pilot study of induction therapy with cyclophosphamide, doxorubicin and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III MO non-small cell lung cancer. Cancer Treat Rep 71:895–900, 1987.PubMedGoogle Scholar
  23. 23.
    Bitran JD, Golomb HM, Hoffman PC et al. Protochemotherapy in non-small cell lung carcinoma. An attempt to increase surgical respectability and survival. A preliminary report. Cancer 57:44–53, 1986.PubMedCrossRefGoogle Scholar
  24. 24.
    Elias AD, Skarin AT, Gonin R et al. Neoadjuvant treatment of stage IIIA non-small cell lung cancer. Am J Clin Oncol (CCT) 17:26–36, 1994.CrossRefGoogle Scholar
  25. 25.
    Darwish S, Minotti V, Crino L et al. Neoadjuvant cisplatin and etoposide for stage IIIA (clinical N2) non-small cell lung cancer. Am J Clin Oncol (CCT) 17:64–67, 1994.CrossRefGoogle Scholar
  26. 26.
    Martini N, Kris MG, Flehinger BJ et al. Preoperative chemotherapy for stage IIIA (N2) lung cancer: The Sloan-Kettering experience with 136 patients. Ann Thorac Surg 55:1365–1374, 1993.PubMedCrossRefGoogle Scholar
  27. 27.
    Takita H, Blumenson LE, Raghavan D. Neoadjuvant chemotherapy of stage IIIA and B lung carcinoma using the PACCO regimen. J Surg Oncol 59:147–150, 1995.PubMedCrossRefGoogle Scholar
  28. 28.
    Burkes RL, Shepherd FA, Ginsberg RJ et al. Induction chemotherapy with MVP in patients with stage IIIA(N2) unresectable non-small cell lung cancer: The Toronto experience. Proc Amer Soc Clin Oncol 13:327, 1994.Google Scholar
  29. 29.
    Elias AD, Skarin AT, Leong T et al. Neoadjuvant therapy for surgically staged IIIAN2 non-small cell lung cancer. Lung Cancer 17:147–161, 1997.PubMedCrossRefGoogle Scholar
  30. 30.
    Sugarbaker DJ, Herndon J, Kohman LJ, Krasna MJ, Green MR. Results of Cancer and Leukemia Group B Protocol 8935: A multi-institutional phase II trimodality trial for stage IIIA(N2) non-small-cell cancer. J Thorac Cardiovasc Surg 109:473–485, 1995.PubMedCrossRefGoogle Scholar
  31. 31.
    Wagner H Jr, Lad T, Piantadosi S et al. Randomized phase II evaluation of preoperative radiation therapy and preoperative chemotherapy with Mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung: LCSG 881. Chest 106(suppl 6):348S–354S, 1994.Google Scholar
  32. 32.
    Dautzenberg B, Benichou J, Allard P et al. Failure of the perioperative PCV neoadjuvant polychemotherapy in resectable bronchogenic non-small cell carcinoma: Results from a randomized phase II trial. Cancer 65:2435–2441, 1990.PubMedCrossRefGoogle Scholar
  33. 33.
    Kumar P, Herndon J II, Langer M et al. Patterns of disease failure after trimodality therapy on non-small cell lung carcinoma pathologic stage IIIA(N2): Analysis of Cancer and Leukemia Group B Protocol 8935. Cancer 77:2393–2399, 1996.PubMedCrossRefGoogle Scholar
  34. 34.
    Shepherd FA. Induction chemotherapy for locally advanced non-small cell lung cancer. Ann Thorac Surg 55:1585–1592, 1993.PubMedCrossRefGoogle Scholar
  35. 35.
    Sause WT, Scott C, Taylor S et al. Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198–205, 1995.PubMedCrossRefGoogle Scholar
  36. 36.
    Le Chevalier T, Arriagada R, Quoix E et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417–423, 1991.PubMedCrossRefGoogle Scholar
  37. 37.
    Tannock IF. Treatment of cancer with radiation and drugs. J Clin Oncol 14:3156–3174, 1996.PubMedGoogle Scholar
  38. 38.
    Arriagada R, Le Chevalier T, Quiox E et al. ASTRO (American Society of Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma. A randomized study of 353 patients. GETCB (Groupe d’Etude et Traitement des Cancers Bronchiques), FNCLCC (Federation Nationale des Centeres de Lutte contre le Cancer) and the CEBI trialists. Intl J Radiat Oncol Biol Phys 20:1183–1190, 1991.CrossRefGoogle Scholar
  39. 39.
    Schaake-Koning C, Van Den Bogaert W, Daleisio O et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524–530, 1992.PubMedCrossRefGoogle Scholar
  40. 40.
    Jeremic R, Shibamoto Y, Acimovic L et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III nonsmall-cell lung cancer: A randomized study. J Clin Oncol 14:1065–1070, 1996.PubMedGoogle Scholar
  41. 41.
    Saunders M, Dische S, Barrett A et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomized multicentre trial. CHART Steering Committee. Lancet 350:161–165, 1997.PubMedCrossRefGoogle Scholar
  42. 42.
    Furuse K, Fukuoka M, Takada Y et al. Phase III study of concurrent vs. sequential thoracic radiotherapy (TRT) in combination with mitomycin (M), vindesine (V) and cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC): Five-year median follow-up results. Proc Amer Soc Clin Oncol 18:458a, 1999.Google Scholar
  43. 43.
    Faber LP, Kittle CF, Warren WH et al. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg 47:669–677, 1989.PubMedCrossRefGoogle Scholar
  44. 44.
    Albain KS, Rusch VW, Crowley JJ et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N2) and IIIB non-smallcell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:1880–1892, 1995.PubMedGoogle Scholar
  45. 45.
    Eberhardt W, Wilke H, Stamatis G et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: Mature results of a phase II trial. J Clin Oncol 16:622–634, 1998.PubMedGoogle Scholar
  46. 46.
    Thomas M, Rhbe C, Semik M et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III nonsmall-cell lung cancer. J Clin Oncol 17:1185–1193, 1999.PubMedGoogle Scholar
  47. 47.
    Choi NC, Carey RW, Daly W et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 15:712–722, 1997.PubMedGoogle Scholar
  48. 48.
    Abain K, Rusch V, Crowley J et al. Long-term survival after concurrent cisplatin/etoposide (PE) plus chest radiotherapy (RT) followed by surgery in bulky, stages IIIA(N2) and IIIB non-small cell lung cancer (NSCLC): 6-year outcomes from Southwest Oncology Group Study 8805. Proc Amer Soc Clin Oncol 18:467a, 1999.Google Scholar
  49. 49.
    Fleck J, Camargo J, Godoy D et al. Chemoradiation therapy (CRT) vs. chemotherapy (CT) alone as neoadjuvant treatment for stage III non-small lung cancer (NSCLC): Preliminary report of a phase III prospective randomized trial. Proc Amer Soc Clin Oncol 12:1108a, 1993.Google Scholar
  50. 50.
    Thomas M, Rhbe C, Semik M et al. Randomized trial of chemotherapy (CT) and twice-daily chemoradiation (hfRT/CT) versus chemotherapy (CT) alone before surgery in stage III non-small cell lung cancer: Interim analysis of toxicity. Proc Amer Soc Clin Oncol 18:1769a, 1999.Google Scholar
  51. 51.
    Albain K, Rusch V, Turrisi A et al. for the Lung Cancer Intergroup. Interim update of the National Cancer Institute High Priority North American Intergroup Trial 0139 (RTOG 9309) for stage III(N2) non-small cell lung cancer: A phase III comparison of concurrent chemotherapy plus standard radiotherapy versus concurrent chemotherapy plus radiotherapy followed by surgical resection. Proc Perugia Internatl Cancer Conf 6:35–37, 1998.Google Scholar
  52. 52.
    Shepherd FA, Johnston MR, Payne D et al. Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: A National Cancer Institute of Canada Clinical Trials Group study. Br J Cancer 78:683–685, 1998.PubMedCrossRefGoogle Scholar
  53. 53.
    Inculet R, Scott C, Dar AR et al. Phase III study comparing chemotherapy and radiation with preoperative chemotherapy and surgical resection in patients with non-small cell lung cancer with spread to mediastinal lymph nodes: A Radiation Therapy Oncology Group study (RTOG 89–01). Lung Cancer 18(Suppl. 1):65, 1997.CrossRefGoogle Scholar
  54. 54.
    Elias A, Herndon J, Kumar P et al. A phase III comparison of “best local-regional therapy” with or without chemotherapy for stage IIIA T1–3N2 non-small cell lung cancer (NSCLC): Preliminary results. Proc Amer Soc Clin Oncol 16:448a,1997.Google Scholar
  55. 55.
    Overholt RH, Neptune WB, Ashraf MM. Primary cancer of the lung: A 42-year experience. Ann Thorac Surg 20:511–519, 1975.PubMedCrossRefGoogle Scholar
  56. 56.
    Shields TW, Yee J, Conn JH et al. Relationship of cell type and lymph node metastasis to survival after resection of bronchial carcinoma. Ann Thorac Surg 20:501–510, 1975.PubMedCrossRefGoogle Scholar
  57. 57.
    Kirsh MM, Rotman H, Argenta L et al. Carcinoma of the lung: Results of treatment over ten years. Ann Thorac Surg 21:371–377, 1976.PubMedCrossRefGoogle Scholar
  58. 58.
    Kemeny MM, Block LR, Braunn DW Jr et al. Results of surgical treatment of carcinoma of the lung by stage and cell type. Surg Gynecol Obstet 147:865–871, 1978.PubMedGoogle Scholar
  59. 59.
    Hilaris BS, Gomez J, Nori D et al. Combined surgery, intraoperative brachytherapy, and postoperative external radiation in stage III non-small cell lung cancer. Cancer 55:1226–1231, 1985.PubMedCrossRefGoogle Scholar
  60. 60.
    PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-smallcell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet 352:257–263, 1998.CrossRefGoogle Scholar
  61. 61.
    Pisters KMW, Kris MG, Gralla RJ et al. Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non-small cell lung cancer. J Surg Oncol 56:236–241, 1994.PubMedCrossRefGoogle Scholar
  62. 62.
    Holmes EC, Gail M, for the Lung Cancer Study Group. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol 4:710–715, 1986.PubMedGoogle Scholar
  63. 63.
    Lad T, Rubinstein L, Sadeghi A, for the Lung Cancer Study Group. The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. J Clin Oncol 6:9–17, 1988.Google Scholar
  64. 64.
    Niiranen A, Niitamo-Korhonen S, Kouri M et al. Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: A randomized study. J Clin Oncol 10:1927–1932, 1992.PubMedGoogle Scholar
  65. 65.
    Wada H, Hitomi S, Teramatsu T et al. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J Clin Oncol 14:1048–1054, 1996.PubMedGoogle Scholar
  66. 66.
    Stewart LA, Pignon JP, Arriagada R et al. A meta-analysis using individual patient data from randomized clinical trials (RCTS) of chemotherapy (CT) in nonsmall-cell lung cancer (NSCLC): (1) Survival in the surgical setting. Proc Am Soc Clin Oncol 13:336, 1994.Google Scholar
  67. 67.
    Keller SM, Adak S, Wagner HJ et al. Randomized prospective comparison of adjuvant mediastinal radiation (RT) with or without concurrent chemotherapy with cisplatin and etoposide (PE) for patients with completely resected T1–3N12M0 non-small cell lung cancer (NSCLC): US. Int J Rad Oncol Biol Phys 45(3)(suppl. 1):145–146, 1999.CrossRefGoogle Scholar
  68. 68.
    Pisters KMW, Ginsberg RJ, Putnam JB et al. Induction paclitaxel and carboplatin (PC) in early stage non-small cell lung cancer (NSCLC): Early results of a completed phase II trial. Proc Amer Soc Clin Oncol 18:467a, 1999.Google Scholar
  69. 69.
    de Boer RH, Smith IE, Pastorino U et al. Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: A randomized feasibility study justifying a multicenter phase III trial. Br J Cancer 79:1514–1518, 1999.PubMedCrossRefGoogle Scholar
  70. 70.
    Pass HI, Pogrebniak HW, Steinberg SM et al. Randomized trial of neoadjuvant therapy for lung cancer: Interim analysis. Ann Thorac Surg 53:992–998, 1992.PubMedCrossRefGoogle Scholar
  71. 71.
    Rosell R, Gomez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with nonsmall-cell lung cancer. N Engl J Med 330:153–158, 1994.PubMedCrossRefGoogle Scholar
  72. 72.
    Rosell R, Gomez-Codina J, Camps C et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: A 7-year assessment of a randomized controlled trial. Lung Cancer 26:7–14, 1999.PubMedCrossRefGoogle Scholar
  73. 73.
    Roth JA, Fossela F, Komaki R et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-smallcell lung cancer. J Natl Cancer Inst 86:673–680, 1994.PubMedCrossRefGoogle Scholar
  74. 74.
    Roth JA, Atkinson EN, Fossela F et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21:1–6, 1998.PubMedCrossRefGoogle Scholar
  75. 75.
    Yoneda S, Hibino S, Gotoh I et al. A comparative trial of induction chemoradiotherapy followed by surgery (CRS) or immediate surgery (IS) for stage III non-small cell lung cancer (NSCLC). Proc Amer Soc Clin Oncol 14:1128a, 1995.Google Scholar
  76. 76.
    Depierre A, Milleron B, Moro D et al. Phase III trial of neoadjuvant chemotherapy (NCT) in resectable stage I (except T1NO), II, IIIa non-small cell lung cancer (NSCLC): The French experience. Proc Amer Soc Clin Oncol 18:465a, 1999.Google Scholar
  77. 77.
    Pisters KM, Kris MG, Gralla RJ et al. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: Implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol 11:1757–1762, 1993.PubMedGoogle Scholar
  78. 78.
    Roberts JR, DeVore RF, Carbone DP et al. Neoadjuvant chemotherapy increases perioperative complications in patients undergoing resection of NSCLC. Proc Amer Soc Clin Oncol 18:1794a, 1999.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Joseph I. Clark
    • 1
  • Kathy S. Albain
    • 1
  1. 1.Loyola University Medical CenterMaywoodUSA

Personalised recommendations